Ertapenem

Restricted
C difficile risk
Medium
Oral Bioavailability
N/A

Dosing

3 months-12 years: IM/IV 30 mg/kg/DAY divided q12h

12 years & up: IM/IV 1000mg/DAY given as a single daily dose. Max: 1000mg/DAY

Safety and efficacy of ertapenem in neonates have not been established, therefore dosages are not available.

Renally cleared, requires dosage adjustment with changes in renal function. Consult a pharmacist for renal dosing.

General Information

Targeted therapy of ESBL infections and other resistant gram negative infections

Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity

Renal and hepatic function, CBC

  • Immediate and delayed-type allergy

  • GI disturbance

  • Cytopenias, eosinophilia, positive Coombs

  • Liver enzyme abnormalities

Valproic acid - carbapenems decrease valproate levels and may decrease seizure threshold.

ID consult recommended

Antimicrobial class: Carbapenem

Average serum half life:

  • Infants 3 months and older, and children: 2.5hrs

  • Adolescents and Adults: 4 hrs

Route of Elimination:

  • Non-CYP-mediated hydrolysis to inactive metabolite

  • Urine (80%(38% as unchanged drug)) and feces (10%)